Wegovy\'s current status: the quick answer
Wegovy is FDA-approved, in stock, and available in the United States as of early 2026. Novo Nordisk sells it directly to uninsured patients for $499 per month through NovoCare Pharmacy. The drug carries three FDA indications: chronic weight management in adults (2021), pediatric obesity in adolescents 12 and older (2022), and reduction of major adverse cardiovascular events in adults with obesity and established cardiovascular disease (March 2024). The multi-year shortage was officially resolved by the FDA in February 2025.
For most of 2022, 2023, and 2024, Wegovy was the most-discussed prescription drug in the United States. It alternated between national headlines about celebrity weight loss, FDA shortage announcements, congressional hearings on drug pricing, and quarterly earnings reports that briefly made Novo Nordisk the most valuable company in Europe. The picture in 2026 is calmer but more consequential: supply has stabilized, a direct-to-patient self-pay channel exists, and a cardiovascular indication has unlocked partial Medicare Part D coverage. None of that changes the central fact that semaglutide is patent-protected and there is no generic Wegovy on the horizon for several more years.
This page is the news and background brief — what changed, when, and why it matters. For the clinical guide, see the main Wegovy patient guide. For pricing detail, see how much Wegovy costs. For supply and pharmacies, see where to buy Wegovy.
Brief 02
Wegovy FDA approval timeline
Wegovy was developed by Novo Nordisk on the back of a decade of research into semaglutide for type 2 diabetes (which became Ozempic in 2017). The same molecule, dosed higher and titrated more aggressively, became the basis for Wegovy. The FDA has expanded the label three times since the original approval.
| Date | FDA action | What it means |
|---|---|---|
| June 4, 2021 | Original approval | Approved for chronic weight management in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with one or more weight-related conditions. |
| December 23, 2022 | Pediatric extension | Approved for adolescents 12 years and older with obesity (BMI at or above 95th percentile for age and sex). First weekly GLP-1 approved for pediatric obesity. |
| March 8, 2024 | Cardiovascular indication | Approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. Based on the SELECT trial. |
| February 2025 | Shortage resolved | FDA removed all five Wegovy doses from the official Drug Shortages list after Novo Nordisk confirmed sustained supply. |
The 2024 cardiovascular approval is the most clinically significant of the post-launch updates. It moved Wegovy from a "lifestyle" obesity drug into the same regulatory category as cholesterol and blood pressure medications, and it allowed Medicare Part D plans to cover Wegovy for the first time — though only for the cardiovascular indication, not for weight loss alone (Source: CMS guidance, 2024).
Brief 03
Who makes Wegovy: Novo Nordisk
Wegovy is made by Novo Nordisk, a Danish pharmaceutical company founded in 1923 in Copenhagen as a manufacturer of insulin. Today Novo Nordisk is one of the world\'s largest pharmaceutical companies by market capitalization and the global leader in diabetes care. The company employs more than 70,000 people in roughly 80 countries and produces about half of the world\'s insulin supply.
Novo Nordisk\'s scientific identity has always been built around peptide hormones — first insulin, then GLP-1 analogs, then more recently amylin and other incretin pathways. Semaglutide is the company\'s most successful product. The active ingredient appears under three different brand names made by Novo Nordisk:
- Ozempic — semaglutide injection for type 2 diabetes, approved in 2017. Doses: 0.25 mg to 2.0 mg weekly.
- Rybelsus — semaglutide oral tablet for type 2 diabetes, approved in 2019. The first oral GLP-1.
- Wegovy — semaglutide injection for chronic weight management, approved in 2021. Doses: 0.25 mg to 2.4 mg weekly.
The company is publicly traded under the ticker NVO on the New York Stock Exchange (American depositary receipts) and as NOVO-B on Nasdaq Copenhagen. Wegovy and Ozempic combined now generate the majority of Novo Nordisk\'s revenue and have driven the company\'s stock to repeatedly trade as the largest in Europe by market value. Investors track the company closely because semaglutide sales now drive overall earnings expectations for the entire global GLP-1 category.
Novo Nordisk is controlled by the Novo Nordisk Foundation, a Danish enterprise foundation that holds the majority of voting rights through Novo Holdings A/S. The foundation reinvests dividends into biomedical research, and it is one of the largest charitable foundations in the world.
Brief 04About Novo Nordisk and the semaglutide pipeline
Beyond the three approved semaglutide products, Novo Nordisk has an active pipeline of next-generation obesity and metabolic drugs. The most-watched candidates as of 2026:
| Candidate | Class | Indication studied | Status |
|---|---|---|---|
| CagriSema | Cagrilintide + semaglutide combo | Obesity, type 2 diabetes | Phase 3 (REDEFINE program) |
| Amycretin | Dual GLP-1 + amylin agonist | Obesity | Phase 1/2 (oral and injectable) |
| Oral semaglutide 25/50 mg | Oral GLP-1 | Obesity (high-dose oral version) | Phase 3 (OASIS program) |
| Semaglutide for Alzheimer\'s | GLP-1 (existing molecule) | Early Alzheimer\'s disease | Phase 3 (evoke / evoke+ trials) |
| Semaglutide for MASH | GLP-1 (existing molecule) | Metabolic-associated steatohepatitis | Phase 3 (ESSENCE) |
The two most commercially important readouts are CagriSema, which Novo Nordisk hopes will produce weight loss closer to or beyond tirzepatide (Zepbound), and oral semaglutide at higher doses, which would let patients take a pill instead of an injection. Both are direct competitive responses to Eli Lilly\'s Zepbound and to the upcoming Lilly oral GLP-1 candidate orforglipron.
Brief 05Generic Wegovy: is there one?
No. There is no FDA-approved generic Wegovy. The generic name of the active ingredient is semaglutide, but a generic name is not the same thing as a generic drug. A generic drug is a version produced by a different manufacturer after the originator\'s patents have expired and the FDA has approved a bioequivalent version. None of those conditions are met for semaglutide in the United States as of 2026.
Novo Nordisk holds a family of US patents covering semaglutide as a composition of matter, its formulation, its dosing regimen, and its delivery device. The earliest of these are projected to expire around 2031, with additional patents extending into 2032 and 2033. Patent litigation may extend or shorten that window. Even when the patents do expire, generic injectable peptides are technically harder to make than generic small-molecule pills, and the FDA approval pathway for a generic biologic peptide is more involved. Industry analysts generally expect the first true generic semaglutide injection in the US no earlier than 2032-2033 (Source: Novo Nordisk patent disclosures and FDA Orange Book listings).
During the 2022-2025 shortage, the FDA temporarily allowed state-licensed and 503A/503B compounding pharmacies to produce "compounded semaglutide" because Wegovy and Ozempic were on the official drug shortage list. Compounded semaglutide is not generic Wegovy. It is not FDA-approved, it is not bioequivalent, and the FDA has issued multiple warning letters about purity, potency, and the use of unapproved salt forms (such as semaglutide sodium and semaglutide acetate). Once the shortage was resolved in February 2025, that enforcement discretion ended for most compounders. The FDA has since taken legal action against compounding entities that continued to produce semaglutide outside an active shortage.
For a comparison of authentic Wegovy versus compounded versions, see our where to buy Wegovy guide.
Brief 06Recent Wegovy price changes
Wegovy launched in 2021 at a list price of approximately $1,349 per month and held that price through 2024. Two unrelated events in 2024 and 2025 changed the picture for self-pay patients.
The first event was the November 2023 launch of Eli Lilly\'s Zepbound (tirzepatide), which entered the obesity market with stronger weight loss data from SURMOUNT-1 and a slightly lower list price. Through 2024, Lilly aggressively expanded its own self-pay channel, LillyDirect, eventually offering tirzepatide vials (single-dose, multi-strength) at prices between $349 and $499 per month for cash-paying patients. This created clear price pressure on Novo Nordisk and on the entire GLP-1 category.
The second event was Novo Nordisk\'s response. In 2025, Novo Nordisk launched NovoCare Pharmacy, a direct-to-consumer cash-pay channel that sells all five Wegovy dose strengths for a flat $499 per month to uninsured US patients with a valid prescription. The price applies regardless of dose, removing the financial incentive to delay dose escalation. NovoCare Pharmacy ships from Novo Nordisk\'s own fulfillment partner, bypassing traditional retail and wholesale markups. (Source: Novo Nordisk press releases, 2025.)
| Channel | Approximate monthly cost (2026) |
|---|---|
| Retail pharmacy, no insurance | $1,200 - $1,450 |
| NovoCare Pharmacy self-pay | $499 (flat, all doses) |
| Commercial insurance + NovoCare Savings Card | $0 - $25 (eligible patients) |
| Medicare Part D (cardiovascular indication only) | Plan-dependent copay |
Full pricing detail is in our Wegovy cost guide, and the side-by-side with Zepbound is covered in Wegovy vs Zepbound.
Brief 07Current shortage status
Wegovy was on the FDA Drug Shortages list from March 2022 through February 2025, an unusually long stretch for a major branded drug. The cause was straightforward: demand outran the global injectable peptide manufacturing base. Novo Nordisk could only produce a finite number of pre-filled pens per quarter, and a viral wave of celebrity-driven demand in 2022-2023 pushed orders far beyond that ceiling. The starting doses (0.25 mg and 0.5 mg) were the most consistently constrained because new patients all begin there.
To resolve the shortage, Novo Nordisk announced and executed several billion dollars of capacity expansion: new fill-finish lines at its Kalundborg, Denmark site; the acquisition of three Catalent fill-finish facilities (in Bloomington, Indiana; Brussels, Belgium; and Anagni, Italy) through Novo Holdings\' purchase of Catalent in 2024; and expanded API production capacity. By late 2024 and into early 2025, all five Wegovy dose strengths were consistently in supply.
On February 21, 2025, the FDA officially removed Wegovy from the Drug Shortages list (Source: FDA Drug Shortages database). As of early 2026, all doses are listed as "Resolved" and no new shortage notifications have been issued. The end of the shortage also ended the legal basis for most compounded semaglutide production, and the FDA has been more aggressive in enforcement against ongoing compounders.
Brief 08Wegovy lawsuits: what is publicly known
Like any widely prescribed drug, Wegovy is the subject of product liability litigation. The largest body of cases concerns gastrointestinal adverse events — primarily gastroparesis (delayed gastric emptying), severe persistent vomiting, intestinal obstruction (ileus), and in some cases hospitalization. Plaintiffs have filed cases against both Novo Nordisk (for Wegovy and Ozempic) and Eli Lilly (for Mounjaro).
In February 2024, the US Judicial Panel on Multidistrict Litigation consolidated the federal cases into MDL 3094, "In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation," in the Eastern District of Pennsylvania. As of 2024-2025, the MDL contains hundreds of plaintiff filings. Bellwether cases have been selected and are working through the discovery process.
Novo Nordisk\'s public position is that Wegovy\'s FDA-approved label already discloses the gastrointestinal side effects in question and that the company will defend the cases. No class-wide settlement has been reached and no court has yet ruled on the central scientific or labeling questions. We do not speculate beyond this, and patients with concerns about side effects should speak with their prescriber. The FDA maintains an ongoing review of post-marketing reports for the entire GLP-1 class.
For the FDA-labeled side effect frequencies, see our main Wegovy guide. For guidance on talking to a provider about side effects, see finding a Wegovy provider.
Brief 09Ongoing clinical trials and upcoming indications
Novo Nordisk continues to study semaglutide in indications beyond weight loss and diabetes. Several large trials have already reported results that may eventually expand the Wegovy label or create new branded products. The most significant trials in the pipeline as of 2026:
- SELECT (cardiovascular outcomes) — completed and published in The New England Journal of Medicine in November 2023. Showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease. Direct basis for the March 2024 FDA cardiovascular indication.
- STEP HFpEF and STEP HFpEF DM — published 2023-2024, showed semaglutide improved heart failure symptoms and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, with and without diabetes.
- FLOW (chronic kidney disease) — completed early 2024, showed semaglutide reduced the risk of major kidney events in patients with type 2 diabetes and CKD. May eventually broaden the Ozempic label.
- ESSENCE (MASH) — Phase 3 trial in metabolic dysfunction-associated steatohepatitis, the modern name for NASH. Topline results due in the 2025-2026 window.
- evoke and evoke+ (Alzheimer\'s) — two Phase 3 trials of oral semaglutide in early Alzheimer\'s disease. Readouts expected in late 2025.
- REDEFINE (CagriSema) — Phase 3 program for the cagrilintide-semaglutide combination, a next-generation obesity therapy.
If even some of these readouts are positive, the next decade of semaglutide news will be less about supply and price and more about new approved uses. For now, the practical question for most patients remains the same one Wegovy was launched to address in 2021: chronic weight management.
To compare Wegovy with the current alternatives, see all GLP-1 weight loss drugs compared and Wegovy vs Zepbound.
Frequently Asked Questions
What is the latest Wegovy news?
As of early 2026, the most consequential Wegovy developments are the FDA cardiovascular indication added in March 2024, the launch of Novo Nordisk's direct-to-consumer NovoCare Pharmacy at $499 per month in 2025, and the FDA declaring the multi-year Wegovy shortage resolved in February 2025. Novo Nordisk has also continued to publish data from the SELECT cardiovascular outcomes trial and the STEP HFpEF series in heart failure.
Who makes Wegovy?
Wegovy is manufactured by Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsvaerd, near Copenhagen. Novo Nordisk has produced insulin and diabetes medications for more than a century and is the world's largest insulin manufacturer. The company also makes Ozempic and Rybelsus (both semaglutide for type 2 diabetes), Saxenda (liraglutide for weight loss), and the older Victoza (liraglutide for diabetes).
Is there a generic version of Wegovy?
No. There is no FDA-approved generic Wegovy. The generic (non-proprietary) name of the active ingredient is semaglutide, but Novo Nordisk holds patents on semaglutide that are expected to begin expiring around 2031-2033 in the United States. Until then, no generic manufacturer can legally produce or sell a bioequivalent version. Compounded semaglutide sold during the 2022-2025 shortage was not FDA-approved and is not the same as a generic.
When will generic Wegovy be available?
The earliest US patents on semaglutide are projected to expire around 2031, with additional patents extending through 2033 depending on litigation outcomes. Even after patent expiration, a generic injectable peptide is technically and regulatory-difficult to produce, so analysts expect generic Wegovy to enter the US market no earlier than 2032-2033, and possibly later. Outside the US, India and Canada may see generic semaglutide sooner.
When did the FDA approve Wegovy?
The FDA approved Wegovy on June 4, 2021 for chronic weight management in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with at least one weight-related comorbidity. In December 2022 the FDA expanded the approval to adolescents 12 years and older with obesity. In March 2024 the FDA added a cardiovascular indication, allowing Wegovy to be prescribed to reduce the risk of major adverse cardiovascular events in adults with obesity and established cardiovascular disease.
Is Wegovy still in shortage?
No. The FDA officially declared the Wegovy shortage resolved in February 2025 after Novo Nordisk significantly expanded production capacity, including new fill-finish lines in Denmark, France, and the United States. All five Wegovy dose strengths are now listed as available on the FDA Drug Shortages database. As a result, FDA enforcement discretion that had allowed compounding pharmacies to produce semaglutide ended, and the FDA has stepped up action against compounders.
Is Novo Nordisk being sued over Wegovy?
Yes, Novo Nordisk faces ongoing product liability litigation related to Wegovy and Ozempic, primarily concerning gastroparesis (delayed stomach emptying), severe vomiting, and intestinal obstruction. As of 2024-2025, hundreds of cases were consolidated in a federal multi-district litigation (MDL 3094) in the Eastern District of Pennsylvania. Novo Nordisk has stated that Wegovy's label already lists these gastrointestinal effects and that it will defend the cases. Litigation is ongoing and no class-wide settlement has been reached.
What is Novo Nordisk stock symbol?
Novo Nordisk is publicly traded on the New York Stock Exchange under the ticker symbol NVO (American depositary receipts) and on the Nasdaq Copenhagen exchange under the ticker NOVO-B. The company is one of the largest in Europe by market capitalization and the most valuable company headquartered in Denmark. Wegovy and Ozempic together account for the majority of Novo Nordisk's revenue growth in recent years.
What is the difference between Wegovy and the generic name semaglutide?
Wegovy is the brand name; semaglutide is the generic (non-proprietary) name of the active ingredient. Saying "generic semaglutide" can be misleading: there is no FDA-approved generic version of the drug. The same active molecule, semaglutide, is also sold under the brand names Ozempic (for type 2 diabetes, also injected weekly) and Rybelsus (an oral tablet for type 2 diabetes). All three are made by Novo Nordisk and are protected by the same patent family.
What new Wegovy indications are in clinical trials?
Novo Nordisk has active or recently completed trials studying semaglutide for heart failure with preserved ejection fraction (STEP HFpEF, results published 2023-2024), chronic kidney disease in patients with type 2 diabetes (FLOW trial), Alzheimer's disease (evoke and evoke+), metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), and addiction-related disorders. Some of these may eventually become new FDA-approved indications for Wegovy, Ozempic, or future semaglutide products.